Tradjenta approved as Type 2 diabetes treatment
SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for Type 2 diabetes, the agency said Monday.
The FDA announced the approval of Tradjenta (linagliptin), made by Indianapolis-based Eli Lilly and German drug maker Boehringer Ingelheim.
“This approval provides another treatment option for the millions of Americans with Type 2 diabetes,” FDA Division of Metabolism and Endocrinology Products director Mary Parks said. “It is effective when used alone or when added to existing treatment regimens.”
Watson announces launch of Generess Fe, patient support program
PARSIPPANY, N.J. — Watson Pharmaceuticals has launched a low-dose chewable contraceptive, the company said Monday.
Watson announced the U.S. commercial launch of Generess Fe (norethindrone and ethinyl estradiol chewable tablets, and ferrous fumarate chewable tablets) in the 0.8-mg/25-mcg strength.
As part of the launch, Watson has created the “I am Generess” patient support program, which caps participant cost for the drug at $25 per prescription and donates $5 in the person’s name to one or more women’s charities of the patient’s choosing, including the National Coalition Against Domestic Violence; the Rape, Abuse and Incest National Network; and the Society for Women’s Health Research.
NACDS elects new 2011-2012 officers at Annual Meeting
SCOTTSDALE, Ariz. — The National Association of Chain Drug Stores announced that Robert Loeffler will succeed Larry Merlo as the organization’s new board of directors chairman, and also announced the appointment of several other elected officers, at its 2011 Annual Meeting.
Loeffler, who serves as H-E-B’s chief administrative officer, will replace Merlo, who is CVS Caremark president and CEO, as NACDS board chairman. Additionally, Walgreens president and CEO Greg Wasson was elected vice chairman, while Thrifty White president and CEO Robert Narveson was named treasurer.
“I congratulate Bob Loeffler on his election as NACDS chairman of the board,” said NACDS president and CEO Steve Anderson. “During his service as an officer on the NACDS board, as chairman of the NACDS Political Action Committee and as an active participant in the NACDS RxImpact grassroots advocacy program, Bob has demonstrated his unyielding commitment to pharmacy. We all look forward to working with him in his new role with NACDS in the coming year."
In addition to the election of the new officers for one-year terms, NACDS members also elected two new executive committee members, which included Narveson and Michael Kaufmann, pharmaceutical CEO of Medicine Shoppe International.
Four new board members also were elected: Jose Barra, SVP health care and beauty at Target; Jerry Cline, SVP retail sales and marketing for Good Neighbor Pharmacy; Lynne Fruth, chairman of the board for Fruth Pharmacy; and Steve Kaczynski, Navarro Discount Pharmacy CEO. These four new board members will join the other 21 members of the NACDS board of directors to develop NACDS’ policies and priorities, the association said.